[go: up one dir, main page]

ES2066062T3 - Preparacion de liberacion sostenida para administracion al cerebro. - Google Patents

Preparacion de liberacion sostenida para administracion al cerebro.

Info

Publication number
ES2066062T3
ES2066062T3 ES90115389T ES90115389T ES2066062T3 ES 2066062 T3 ES2066062 T3 ES 2066062T3 ES 90115389 T ES90115389 T ES 90115389T ES 90115389 T ES90115389 T ES 90115389T ES 2066062 T3 ES2066062 T3 ES 2066062T3
Authority
ES
Spain
Prior art keywords
brain
preparation
administration
sustained release
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90115389T
Other languages
English (en)
Inventor
Toru Hayakawa
Toshiki Yoshimine
Keiji Fujioka
Yoshihiro Takada
Yoshio Sasaki
Tsunemasa Irie
Nobuyuki Fukushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Koken Co Ltd
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd, Sumitomo Pharmaceuticals Co Ltd filed Critical Koken Co Ltd
Application granted granted Critical
Publication of ES2066062T3 publication Critical patent/ES2066062T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE EL USO DE UNA SUSTANCIA FARMACEUTICAMENTE ACTIVA PARA EL TRATAMIENTO DE ENFERMEDADES CEREBRALES MEDIANTE LA ADMINISTRACION AL CEREBRO DE DICHA SUSTANCIA EN FORMA DE UNA PREPARACION QUE COMPRENDE A DICHA SUSTANCIA INCORPORADA EN UN PORTADOR BIODEGRADABLE.
ES90115389T 1989-08-10 1990-08-10 Preparacion de liberacion sostenida para administracion al cerebro. Expired - Lifetime ES2066062T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20848489 1989-08-10

Publications (1)

Publication Number Publication Date
ES2066062T3 true ES2066062T3 (es) 1995-03-01

Family

ID=16556927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90115389T Expired - Lifetime ES2066062T3 (es) 1989-08-10 1990-08-10 Preparacion de liberacion sostenida para administracion al cerebro.

Country Status (6)

Country Link
EP (1) EP0412554B1 (es)
JP (1) JP3187410B2 (es)
AT (1) ATE113470T1 (es)
DE (1) DE69013797T2 (es)
DK (1) DK0412554T3 (es)
ES (1) ES2066062T3 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69119759T2 (de) 1990-03-20 1997-01-16 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
ATE226091T1 (de) * 1990-05-16 2002-11-15 Southern Res Inst Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DE4019208A1 (de) * 1990-06-15 1992-03-05 Peter Dr Med Wehling Nervenregenerationsmittel
US5496559A (en) * 1991-04-08 1996-03-05 Sumitomo Pharmaceuticals Company, Limited Porous solid formulations containing proteinaceous physiologically active substances
CA2109955A1 (en) * 1991-05-24 1992-11-26 Toru Hayakawa Equipment for intracerebral administration of preparations
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
DE69637243T2 (de) * 1995-07-03 2008-06-19 Dainippon Sumitomo Pharma Co., Ltd. Atelocollagen enthaltende gen-zusammensetzungen
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
WO1997044057A1 (en) * 1996-05-21 1997-11-27 Cytotherapeutics, Inc. System and method for delivery of cytokines using encapsulated cytokine-secreting cells
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
DE60232149D1 (de) 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
CN108840924A (zh) * 2018-06-20 2018-11-20 罗国球 一种高蛋白含量脑蛋白水解物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139286B1 (en) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Prolonged sustained-release preparations
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Also Published As

Publication number Publication date
JP3187410B2 (ja) 2001-07-11
ATE113470T1 (de) 1994-11-15
DE69013797D1 (de) 1994-12-08
EP0412554B1 (en) 1994-11-02
JPH03163032A (ja) 1991-07-15
EP0412554A2 (en) 1991-02-13
DK0412554T3 (da) 1994-12-12
EP0412554A3 (en) 1991-09-25
DE69013797T2 (de) 1995-05-18

Similar Documents

Publication Publication Date Title
ES2066062T3 (es) Preparacion de liberacion sostenida para administracion al cerebro.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
LU91894I2 (fr) 4-aminopyridine et ses dérivés
ES2074124T3 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
NL300228I1 (nl) Derivaten van 19-nor-vitamine-D.
ES2085337T3 (es) Comprimidos farmaceuticos.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
FI905681A0 (fi) Menetelmä hidastetusti vapauttavien koostumusten valmistamiseksi
TW197423B (es)
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
MX9302711A (es) Preparacion de base.
GR3006606T3 (es)
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
RU97104062A (ru) Применение селегилина для лечения эпилептических заболеваний
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
SE7708622L (sv) 2-bensyl-perhydroazepiner, sett for framstellning derav och lekemedel, innehallande dem
AR024100A1 (es) Amidas de acidos fenilciclohexanocarboxilicos sustituidos
ES2107400T1 (es) Nueva utilizacion terapeutica de superoxidos dismutasas.
ES2085411T3 (es) Uso de heptastigmina en la terapia de ictus cerebral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 412554

Country of ref document: ES